Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results
from the RE-NOVATE(TM) trial demonstrated that oral dabigatran
etexilate once daily, administered for an average of 33 days, was
non-inferior to enoxaparin, also administered for an average of 33
days, in preventing venous thromboemb...
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis
...olorectal
cancer, and preclinical data evaluating the mechanism of NU172, a
short-acting, direct thrombin inhibiting aptamer, will be presented
at the
xxist Congress of the International Society on Thrombosis
and Haemostasis (ISTH) taking place in Geneva, Switzerland, July
6-12, 2007.
The presentatio...
New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
...ignificant 44% reduction in
venous thromboembolism (VTE) events (Deep Vein Thrombosis and / or
Pulmonary Embolism). The findings were presented at the
xxist ISTH
Congress (International Society on Thrombosis and Haemostasis) in
Geneva, Switzerland.
Acutely ill medical patients are at high risk of VTE. Th...
International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
...c International Day for the Evaluation of
Patients at Risk for Venous Thromboembolism in the Acute Hospital
Care Setting) study presented today at the
xxist International
Society on Thrombosis and Haemostasis (ISTH) congress in
Geneva.
VTE is a preventable disease which contributes significantly to
morbi...
Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
...gnificant correlation
between serum levels of the Company's patented AtherOx(TM)
bio-markers and cardiovascular disease. The data was presented at
the
xxist Congress of the International Society on Thrombosis and
Hemostasis (ISTH) in Geneva, Switzerland.
Data released this week shows the association of an...
New Information on the Potential of Plasmin Shared at ISTH Congress
... and
development program for Plasmin (Human), TAL-05-00018, was
presented by Talecris Biotherapeutics, Inc.
(http://www.talecris.com) this week at the
xxist International
Society for Thrombosis and Haemostasis (ISTH) Congress in Geneva,
Switzerland. The information included new data and updates on
continui...
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
...tary forms of
recombinant Factor IX to treat patients with Hemophilia B. The data
were highlighted in an oral presentation and a poster session at
the
xxist Congress of the International Society on Thrombosis and
Haemostasis (ISTH) in Geneva, Switzerland.
Dougald M. Monroe, Ph.D., Associate Professor, UN...